The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...
Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback